Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer - Episode 12

Expert Insights: Investigational ADCs Safety Profiles

,

Panelists discuss how, despite the investigational status of agents like patritumab deruxtecan (HER3-DXd) and datopotamab deruxtecan (Dato-DXd), it’s crucial for community oncologists to be aware of the treatment-related adverse effects (TRAEs) associated with these therapies and to consider effective management strategies as reported in clinical trials.

EP. 1: Overview of Current ADCs in Breast Cancer
EP. 2: ADCs in Breast Cancer: Mechanism of Action, and Components
EP. 3: Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials
EP. 4: Expert Perspectives on the Management of SG-Related Neutropenia
EP. 5: Navigating SG-related Diarrhea
EP. 6: Expert Insights: SG Adverse Events Management including Alopecia & Nausea
EP. 7: Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies
EP. 8: Clinical Management Considerations: Pneumonitis associated with T-DXd
EP. 9: Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies
EP. 10: Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer
EP. 11: Future Perspectives on ADCs in Breast Cancer
Now Viewing
EP. 12: Expert Insights: Investigational ADCs Safety Profiles
EP. 13: Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs

Video content above is prompted by the following:

  • While these agents are still investigational, and their safety profiles have not been officially established…
  • Can you comment on any pertinent treatment-related adverse effects (TRAEs) associated with patritumab deruxtecan (HER3-DXd) reported in these clinical trials that the community oncologists should be aware of and your respective management strategies?
  • Please comment on any pertinent TRAEs associated with datopotamab deruxtecan (Dato-DXd) reported in these clinical trials that the community oncologists should be aware of and your respective management strategies.